The presence of LVI in a tumor is generally considered an adverse prognostic factor. It is often associated with a higher stage of cancer, increased likelihood of lymph node involvement, and a greater risk of distant metastasis. Consequently, the detection of LVI may influence treatment decisions, potentially leading to more aggressive therapy options such as chemotherapy, radiation, or targeted therapies.
